NCT04735536

Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG

A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Cognition Therapeutics · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.

Detailed description

This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD. 16 participants (8 randomized to 300 mg CT1812, 8 randomly assigned to placebo during each treatment period): the 8 participants randomly assigned to CT1812 in Treatment Period 1 will receive placebo in Treatment Period 2; the 8 participants randomly assigned to placebo in Treatment Period 1 will receive CT1812 in Treatment Period 2.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	CT1812	Active Treatment- CT1812 at a dose of 300mg
OTHER	Placebo	Placebo Comparator

Timeline

• Start date: 2020-07-09
• Primary completion: 2023-04-26
• Completion: 2023-04-26
• First posted: 2021-02-03
• Last updated: 2024-11-29
• Results posted: 2024-11-29

Locations

1 site across 1 country: Netherlands

Regulatory

• FDA-regulated drug study